62587-73-9 Usage
Description
Cefsulodin is a semi-synthetic, third-generation cephalosporin antibiotic with a narrow spectrum of activity. It was first synthesized and patented by the Takeda Pharmaceutical Company in 1977. Cefsulodin has activity against Pseudomonas aeruginosa and Staphylococcus aureus but little activity against other bacteria. It is eliminated renally and has a serum half-life similar to ceftazidime and cefoperazone. Cefsulodin appears to be well tolerated and relatively free of any significant toxicity except for nausea and vomiting, which appear to be related to the infusion rate.
Definition
ChEBI: Cefsulodin is a pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic. It has a role as an antibacterial drug. It is a cephalosporin, a primary carboxamide and an organosulfonic acid.
Uses
Cefsulodin is a third generation cephalosporin antibiotic that has very specific activity against Pseudomonas aeruginosa. Cefuslodin is used in CIN (cefsulodin-Irgasan-novobiocin) agar to select for microorganisms such as E. coli. Cefsulodin is a substrate for rat Oatp1a4. It has been used to study multidrug resistance-associated protein 4 in efflux transport of prostaglandin E2 across the mouse blood-brain barrier. Cefsulodin is used to study the effect of expression, binding, and inhibition of PBP1 and other penicillin-binding proteins (PBPs) on bacterial cell wall mucopeptide synthesis.
Therapeutic Function
Antibiotic
Antimicrobial activity
A semisynthetic parenteral cephalosporin supplied as the
sodium salt. Activity against Ps. aeruginosa contrasts strikingly
with poor activity against many other organisms.
Anaerobic Gram-negative rods, Gram-positive rods and cocci
are all resistant. It is stable to many β-lactamases, including the
Ps. aeruginosa chromosomal enzyme, and is a poor substrate
for the enzymes of Enterobacter spp. and Morg. morganii. It is
slowly hydrolyzed by TEM β-lactamases and more rapidly by
the enzymes of some carbenicillin-resistant strains of Ps. aeruginosa,
with which distinct inoculum effects may be seen.
A 500 mg intravenous bolus dose achieves a plasma concentration
of c. 70 mg/L at the end of the injection; the corresponding
intramuscular dose achieves a peak concentration of
around 15 mg/L. The plasma half-life is 1.5 h. About 15–30%
is protein bound.
There is some metabolism of the drug, but the main route
of excretion is via the kidneys, most appearing in the urine
in the first 6 h. The plasma half-life is linearly related to creatinine
clearance, rising to a mean of 10–13 h in patients
where clearance was <10 mL/min, falling to around 2 h on
hemodialysis.
It is well tolerated, apart from nausea and vomiting in some
subjects. It has been used in severe pseudomonas infections,
usually in combination with an aminoglycoside, but treatment
has been complicated on a number of occasions by the emergence
of resistance or superinfection.
It is available in Japan.
Check Digit Verification of cas no
The CAS Registry Mumber 62587-73-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,5,8 and 7 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 62587-73:
(7*6)+(6*2)+(5*5)+(4*8)+(3*7)+(2*7)+(1*3)=149
149 % 10 = 9
So 62587-73-9 is a valid CAS Registry Number.
InChI:InChI=1/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)
62587-73-9Relevant articles and documents
Preparing method of Cefsulodin
-
Paragraph 0050; 0051; 0052; 0053; 0092; 0093; 0094; 0095, (2017/08/27)
The present invention discloses a Preparing method of Cefsulodin, comprising the steps of Intermediate D-alpha-Sulfophenylacetic acid or its salt with acylating agent to form mixed acid anhydride; Key intermediate 7-PACA dissolved in the solvent in the organic base or inorganic base under the a certain temperature to get 7-PACA solution; dropping mixed acid anhydride solution into 7- PACA solution, and to obtain the Cefsulodin after full reaction and treatment. The method adopts the new synthetic method to carry out the 7-position condensation reaction with the mixed acid anhydride method. The new method has mild condition, stable process and easy operation, which is helpful in solving unstable process problems caused by hard production of Sulfophenylacetyl chloride, unstable Acyl chloride, or the instability of the intermediate in the subsequent reaction.
